Komori
Immuno-Biological Laboratories (4570) · RiskMitigated

Risk of Inability to Secure Profits Sufficient for Stable Dividends

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2026.

4entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20192016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Risk of no dividends depending on profit levels and funding needsA theme 9 companies write about · 9 as a headwind · 0 as a tailwind

0 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「As a result, dividends of ¥6 per share will be paid for the current period.」

    The company paid a dividend of ¥6 per share for the current period, and the previously disclosed risk of being unable to secure stable earnings available for dividends was concretely addressed through the recording of profit and payment of a dividend.
  2. FY2019RestatedAnnual report

    「Based on this policy, the company plans to return value to shareholders while considering the balance between dividends and retained earnings. However, as a research and development-oriented company, it may be unable to secure stable earnings available for dividends due to an increase in its research and development expenses and other factors.」

    The company continued to disclose the risk that research and development expenses could prevent it from securing stable earnings available for dividends. It paid no dividend for the current period.
  3. FY2017RestatedAnnual report

    「Based on this policy, the company plans to return value to shareholders while considering the balance between dividends and retained earnings. However, as a research and development-oriented company, it may be unable to secure stable earnings available for dividends due to an increase in its research and development expenses and other factors.」

    The company reiterated the risk that research and development expenses could prevent it from securing stable earnings available for dividends. It paid no dividend for the current fiscal year.
  4. FY2016First statedAnnual report

    「As a research and development-oriented company, the company may be unable to secure stable earnings available for dividends due to an increase in its research and development expenses and other factors.」

    The company paid no dividend for the current period because, among other reasons, it was unable to record a profit, meaning that the risk described has materialized.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.